Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
LTS Lohmann Therapie-Systeme AG
About

LTS - MAP - Microneedle Technology for Pharmaceuticals

SHARE
LTS Lohmann Therapie-Systeme AG provides Microneedle Array Patches (MAP), a microneedle technology offering potential advantages for the delivery of existing vaccines such as influenza, tetanus toxoid, measles-rubella, and Hepatitis B, as well as biologics and small molecules. This innovation allows a pain-free, safe application with options for fast onset and sustained release. Customizable in design, the MAPs can simplify healthcare logistics by potentially eliminating the need for cold chain storage, reducing healthcare costs, and avoiding needlestick injuries. They enable self-administration, which could lower healthcare expenses and increase patient compliance, particularly for those with needlestick phobias or difficulty swallowing. The technology is particularly beneficial for patient groups such as children, older adults, and those requiring complex care.
Most popular related searches
hepatitis B
injectable therapy
therapy system
needle design
skin barrier
patient care
pharmaceuticals
vaccination
vaccine influenza
rubella

MAP – The game changer microneedle technology

Microneedle Patch technology is a delivery system, that shall enable active substances to overcome the skin barrier. It helps to enhance the delivery of a drug through the transdermal/intradermal route overcoming various problems associated with conventional formulations. Our Micro Array Patch (MAP) platform is based on dissolvable needles containing the API, which enables optimal load without relying on liquid reservoirs and offers many advantages for a custom-made design.
 
Configured specifically for the API and release option, each MAP can feature up to 1,000 needles per cm², with needle lengths ranging from 200 up to 1000μm. Microneedle technology is considered as an advantageous delivery route for existing vaccines, including e.g. influenza, tetanus toxoid, measles-rubella, Hepatitis B, as well as for biologics and small molecules.
 

  • New innovative dosage form for pain free and safety application.

  • Suitable for a wide variety of molecules (biologics, vaccines, small molecules).

  • Fast onset and sustained release options available.

  • Possibility to simplify and reduce healthcare costs of injectable therapies and therefore create a superior market position.

  • Custom design options in needle design, length, width and composition.

  • Potential elimination of cold chain and concomitant challenges and costs.

  • Opportunities for life cycle management, product extension and repurposing.

  • Avoidance of needlestick injuries.

  • Comfortable therapy through potential avoidance of cold chain and doctor’s visit.

  • Self-administration creates the potential for lower healthcare costs.

  • Increased compliance due to convenient and pain free application.

  • Ideal for patients with needlestick phobias or difficulty swallowing.

  • Easier for children, older people and patients requiring complex care.